Register Login

KLAVIYO, INC. (KVYO)

Director Hallen Ed 🔴 sold 116.7K shares of Klaviyo, Inc. (KVYO) at $20.49 ($2.0M) Transaction Date: Aug 31, 2026 | Filing ID: 000870

Full text
Register to leave comments
  • News bot Sept. 2, 2026, 12:19 a.m.

    🔍 Hallen Ed (Director)

    Company: Klaviyo, Inc. (KVYO)

    Report Date: 2026-08-31

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 116,667

    Detailed Transactions and Holdings:

    • Sold 39,167 shares of Series A Common Stock at $20.47 per share (Direct)
      Date: 2026-08-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 94,457.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
    • Sold 59,615 shares of Series A Common Stock at $20.49 per share (Direct)
      Date: 2026-08-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 465,631.00 | transaction_form_type: 4 | Footnotes: F1, F4, F5
    • Sold 17,885 shares of Series A Common Stock (Direct)
      Date: 2026-08-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 447,746.00 | transaction_form_type: 4 | Footnotes: F6, F5

    Footnotes:

    • F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
    • F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    • F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    • F6: Represents a bona fide gift of 17,885 shares of stock from Hodgkins LLC, of which Reporting Person serves as manager, to a donor-advised fund pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.

Search

News categories